These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11177319)

  • 41. New federal guidance adds duties for institutional review boards (IRBs).
    Maloney DM
    Hum Res Rep; 2005 Nov; 20(11):1-2. PubMed ID: 16358479
    [No Abstract]   [Full Text] [Related]  

  • 42. Toward protecting the safety of participants in clinical trials.
    Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
    Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Institutional Review Board dilemma: responsible for safety monitoring but not in control.
    DeMets DL; Fost N; Powers M
    Clin Trials; 2006; 3(2):142-8. PubMed ID: 16773956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Examining IRBs: are review boards fulfilling their duties?
    Randal J
    J Natl Cancer Inst; 2001 Oct; 93(19):1440-1. PubMed ID: 11584053
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical Trials, Healthy Controls, and the Birth of the IRB.
    Stark L; Greene JA
    N Engl J Med; 2016 Sep; 375(11):1013-5. PubMed ID: 27626515
    [No Abstract]   [Full Text] [Related]  

  • 46. Local IRBs vs. federal agencies: shifting dynamics, systems, and relationships.
    Klitzman RL
    J Empir Res Hum Res Ethics; 2012 Jul; 7(3):50-62. PubMed ID: 22850143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs.
    Hata T; Nakamura K; Yonemori K; Noguchi E; Watanabe M; Sohn J; Lu YS; Yap YS; Tamura K; Fujiwara Y
    Clin Transl Sci; 2021 May; 14(3):1015-1025. PubMed ID: 33382914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical schools' attitudes and perceptions regarding the use of central institutional review boards.
    Loh ED; Meyer RE
    Acad Med; 2004 Jul; 79(7):644-51. PubMed ID: 15234914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IRBs, data sharing, and privacy of human subjects.
    Maloney DM
    Hum Res Rep; 2002 Apr; 17(4):3. PubMed ID: 12374179
    [No Abstract]   [Full Text] [Related]  

  • 50. Biomedical ethics. Penn report, agency heads home in on clinical research.
    Marshall E
    Science; 2000 Jun; 288(5471):1558-9. PubMed ID: 10858125
    [No Abstract]   [Full Text] [Related]  

  • 51. Using central IRBs for multicenter clinical trials in the United States.
    Flynn KE; Hahn CL; Kramer JM; Check DK; Dombeck CB; Bang S; Perlmutter J; Khin-Maung-Gyi FA; Weinfurt KP
    PLoS One; 2013; 8(1):e54999. PubMed ID: 23383026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network-initiated clinical trials.
    Diamond MP; Eisenberg E; Huang H; Coutifaris C; Legro RS; Hansen KR; Steiner AZ; Cedars M; Barnhart K; Ziolek T; Thomas TR; Maurer K; Krawetz SA; Wild RA; Trussell JC; Santoro N; Zhang H;
    Clin Trials; 2019 Feb; 16(1):3-10. PubMed ID: 30354458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variation among institutional review boards in evaluating the design of a multicenter randomized trial.
    Stark AR; Tyson JE; Hibberd PL
    J Perinatol; 2010 Mar; 30(3):163-9. PubMed ID: 19798046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protecting research subjects--what must be done.
    Shalala D
    N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573
    [No Abstract]   [Full Text] [Related]  

  • 55. [Duration and variation of the ethics approval process in Germany - an example from a non-interventional study with 44 participating centers].
    Eichler M; Schmitt J; Schuler MK
    Z Evid Fortbild Qual Gesundhwes; 2019 Oct; 146():15-20. PubMed ID: 31473073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Public oversight is necessary if human gene therapy is to progress.
    Zallen DT
    Hum Gene Ther; 1996 May; 7(7):795-7. PubMed ID: 8860831
    [No Abstract]   [Full Text] [Related]  

  • 57. An overview of FDA, IRBs and regulations.
    Petricciani JC
    IRB; 1981 Dec; 3(10):1-3, 11. PubMed ID: 11649413
    [No Abstract]   [Full Text] [Related]  

  • 58. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.
    Greene SM; Geiger AM
    J Clin Epidemiol; 2006 Aug; 59(8):784-90. PubMed ID: 16828670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harmonizing regulations for biomedical research: a critical analysis of the US and Venezuelan systems.
    Di Tillio-Gonzalez D; Fischbach RL
    Dev World Bioeth; 2008 Dec; 8(3):167-77. PubMed ID: 17488491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.